Federal regulators, including the Office of Inspector General and CMS contractors, continue to scrutinize compliance involving discarded drug billing and documentation within ambulatory settings. This regulatory attention represents far more than a routine compliance issue. Improper documentation involving high-cost pharmaceuticals and biologics can expose facilities to repayment demands, billing disputes, and significant financial risk. One common vulnerability involves inaccurate tracking of unused portions of single-dose medications and the inconsistent application of required billing modifiers.

The heightened focus on modifiers JW and JZ has created documentation and workflow challenges for many facilities. Centers may be flagged for review when billing records, inventory controls, nursing documentation, and waste logs fail to align. Automated billing systems can occasionally create discrepancies when modifiers are applied incorrectly or inconsistently. As a result, robust inventory management processes, detailed waste documentation, and integrated billing controls are becoming increasingly important. Implementing dual-verification waste logs, synchronizing electronic health record data with pharmacy billing systems, conducting periodic internal audits, and performing revenue integrity reviews are among the most effective ways to reduce revenue leakage and strengthen audit readiness. Facilities that proactively address these issues are better positioned to withstand regulatory scrutiny while protecting reimbursement accuracy and financial performance.